#United States #Upsher-Smith #Duchenne Muscular Dystrophy #Maple Grove #KYMBEE

Upsher-Smith Launches KYMBEE™ (Deflazacort) Tablets

Upsher-Smith Laboratories, LLC has officially launched KYMBEE™ (deflazacort) Tablets, specifically indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 5 years and older. The medication is being manufactured in the United States and is available in multiple strengths: 6 mg, 18 mg, 30 mg, and 36 mg. Distribution will be managed through Orsini Specialty Pharmacy, which is known for its focus on rare diseases and complex therapy solutions.

The introduction of KYMBEE™ is part of Upsher-Smith's commitment to supporting the rare disease community, reinforced through their Promise of Support® Program. This initiative aims to ease the challenges faced by families regarding access and treatment for DMD, providing essential resources for patients and their caregivers. According to Dr. Michelle Zachman, Medical Affairs Director at Upsher-Smith, the company is dedicated to alleviating the stress families encounter while trying to secure necessary medications for DMD.

KYMBEE™ tablets are a crucial addition to the market, given the profound impact Duchenne Muscular Dystrophy has on those affected. DMD is a rare genetic disorder characterized by progressive muscle weakness, predominantly affecting boys. Early diagnosis is critical, and while there is no cure, treatment can help manage the condition and improve the quality of life for patients. The disease affects approximately 15,000 individuals in the U.S. alone, with over 300,000 cases worldwide.

The Promise of Support® program encompasses various forms of assistance, including:

• - Copay assistance: Helping families manage out-of-pocket expenses associated with the medication.
• - Navigating insurance challenges: Providing guidance through the complexities of insurance coverage to ensure patients can access the treatment they need.
• - Access pathways: Developing strategies to ensure therapy access even in the face of insurance complications.
• - Dedicated support team: Offering a team of professionals to support patients and families throughout their treatment journey.

Families interested in KYMBEE™ are encouraged to discuss it with their healthcare providers. For any inquiries regarding the medication or the support program, they can contact Upsher-Smith directly at 1-888-650-3789.

Important Safety Information

While KYMBEE™ offers significant benefits, it is vital for patients and caregivers to be aware of the potential risks associated with its use. Some key points include:

• - Patients with hypersensitivity to deflazacort or any of its components should avoid using KYMBEE™.
• - The medication can alter endocrine functions and requires careful management under a healthcare provider, especially during dosage adjustments to prevent adrenal insufficiency or withdrawal syndrome.
• - An increased susceptibility to infections may occur, necessitating immediate medical advice if symptoms develop.
• - Regular monitoring for mood changes and other side effects is essential for patients receiving this treatment.

Consulting a healthcare provider is crucial before initiating KYMBEE™ therapy, particularly for those who are pregnant, breastfeeding, or taking other medications that could interact adversely.

Overall, the launch of KYMBEE™ signifies a hopeful advancement for those affected by Duchenne Muscular Dystrophy, illustrating Upsher-Smith's commitment to helping patients navigate their healthcare challenges. For more information about KYMBEE™ and the Promise of Support® Program, visit Upsher-Smith's official website.